Recent News

• 12.03.2025 - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
• 12.02.2025 - First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
• 11.25.2025 - KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
• 11.13.2025 - Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
• 11.12.2025 - Kura Oncology to Participate in Upcoming Investor Conference
• 11.04.2025 - Kura Oncology Reports Third Quarter 2025 Financial Results

Recent Filings

• 11.14.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities